Abivax S.A. (ABVX) surged 20.87% during intraday trading on Monday, driven by reports of a potential acquisition by pharmaceutical giant Eli Lilly (LLY).
According to multiple sources, Eli Lilly has entered early discussions with French authorities to explore a possible takeover of the biotech firm. The discussions reportedly include assessing regulatory approval under France's foreign investment screening rules and the potential involvement of state-backed investor Bpifrance as a minority shareholder. The news has fueled investor optimism, leading to a significant rally in Abivax's stock.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments